Alnylam Pharmaceuticals Quarterly Income Statement
NASDAQ: ALNYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Alnylam Pharmaceuticals revenue and earnings
In the quarter ended Jun 30, 2026, Alnylam Pharmaceuticals generated $1.29 billion in revenue, up 66.9% from the same quarter a year earlier. Net income was $164.5 million, for a net margin of 12.7% versus a median of 3.5% in the prior 5 quarters. Gross margin was 76.9% (down from 81.6%) and operating margin 17.9%.
Diluted earnings per share came in at $1.21.
Summary generated from market data by MetaCap's automated system. Methodology
Alnylam Pharmaceuticals income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.29B | — | 1.10B | 1.25B | 773.69M | 594.19M | 593.17M | 500.92M | 659.83M | 494.33M | 439.72M | 750.53M |
| Revenue growth (YoY) | +66.86% | — | +84.95% | +149.35% | +17.26% | +20.20% | +34.90% | -33.26% | +107.00% | +54.82% | +31.25% | +183.96% |
| Cost of Revenue | 298.26M | — | 267.72M | 197.23M | 142.03M | 70.18M | 102.65M | 81.98M | 67.27M | 54.61M | 71.97M | 79.47M |
| Gross Profit | 992.69M | — | 829.31M | 1.05B | 631.66M | 524.01M | 490.52M | 418.94M | 592.55M | 439.72M | 367.74M | 671.06M |
| Operating Expenses | 761.25M | — | 697.59M | 683.81M | 647.86M | 505.93M | 595.68M | 495.84M | 543.94M | 483.15M | 484.15M | 457.19M |
| Research & Development | 413.13M | — | 372.22M | 358.81M | 323.62M | 265.12M | 300.17M | 270.93M | 294.14M | 261.00M | 272.14M | 253.18M |
| Selling, General & Admin | 347.92M | — | 325.37M | 322.08M | 323.31M | 239.95M | 295.34M | 220.99M | 248.40M | 210.80M | 198.12M | 199.18M |
| Operating Income | 231.44M | — | 131.72M | 367.98M | -16.20M | 18.08M | -105.16M | -76.91M | 48.61M | -43.44M | -116.40M | 213.87M |
| Interest Expense | 82.05M | — | 65.40M | 44.40M | 61.46M | 58.31M | 38.97M | 34.38M | 33.26M | 35.25M | 31.34M | 30.89M |
| Other Income (Expense) | -53.63M | — | -45.46M | -129.01M | -25.11M | -20.45M | -88.80M | -31.76M | -59.78M | -20.15M | -21.28M | -63.13M |
| Pretax Income | 177.81M | — | 86.26M | 238.97M | -41.31M | -2.37M | -193.96M | -108.66M | -11.17M | -63.59M | -137.69M | 150.74M |
| Income Tax | 13.31M | — | -25.28M | -12.12M | 30.92M | 15.88M | -110.19M | 2.91M | 5.72M | 2.35M | 183.00K | 2.99M |
| Net Income | 164.49M | 205.99M | 111.54M | 251.08M | -72.23M | -18.25M | -83.76M | -111.57M | -16.89M | -65.94M | -137.87M | 147.75M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | -175.51% | — | — | — | — |
| EPS (Basic) | 1.23 | — | 1.17 | 1.91 | -0.55 | -0.14 | -0.66 | -0.87 | -0.13 | -0.52 | -1.09 | 1.18 |
| EPS (Diluted) | 1.21 | — | 1.18 | 1.84 | -0.55 | -0.14 | -0.66 | -0.87 | -0.13 | -0.52 | -1.06 | 1.15 |
| Shares Outstanding (Basic) | 133.61M | — | — | 131.45M | 130.63M | 129.68M | — | 128.59M | 126.73M | 126.14M | — | 125.22M |
| Shares Outstanding (Diluted) | 138.28M | — | — | 137.35M | 130.63M | 129.68M | — | 128.59M | 126.73M | 126.14M | — | 131.34M |
| EBITDA | — | — | 145.22M | 381.79M | -2.25M | 32.48M | -90.99M | -62.92M | 63.62M | -29.92M | -102.92M | 227.19M |
| Gross Margin | 76.90% | — | 75.60% | 84.21% | 81.64% | 88.19% | 82.69% | 83.63% | 89.80% | 88.95% | 83.63% | 89.41% |
| Operating Margin | 17.93% | — | 12.01% | 29.46% | -2.09% | 3.04% | -17.73% | -15.35% | 7.37% | -8.79% | -26.47% | 28.50% |
| Net Margin | 12.74% | — | 10.17% | 20.10% | -9.34% | -3.07% | -14.12% | -22.27% | -2.56% | -13.34% | -31.35% | 19.69% |
This table shows 12 quarterly periods of Alnylam Pharmaceuticals's income statement, from Q2 2026 back to Q3 2023, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow ALNY's reporting calendar. What is a income statement?